Michael Gosselin
About Michael Gosselin
Current Role at Alkermes
Michael Gosselin is currently the Director of Oral Solid Dose Manufacturing Operations at Alkermes, based in the Dayton, Ohio Area. In this role, he leads the implementation of operational excellence and lean manufacturing initiatives. His responsibilities include overseeing the production processes for oral solid dose formulations, ensuring compliance with regulatory standards, and driving continuous improvement efforts within the manufacturing operations.
Career at Patheon
Before his current role, Michael Gosselin worked at Patheon in various capacities. From 2014 to 2017, he served as the Director of Pharmaceutics and Process Technology in the Cincinnati Area, OH. During his tenure, he focused on advancing pharmaceutical processing technologies and optimizing formulation strategies. Earlier, from 2007 to 2010, he was a Senior Scientist at Patheon Inc., contributing to research and development efforts in pharmaceutical formulations.
Experience at Aptalis Pharma and Eurand
Michael Gosselin held significant positions at Aptalis Pharma and Eurand, Inc. From 2010 to 2014, he served as Manager / Associate Director of Formulations at Aptalis Pharma, where he led formulation development projects. At Eurand, Inc., he worked as a Formulation Scientist I / II from 2002 to 2007, gaining extensive experience in the design and optimization of drug formulations.
Educational Background
Michael Gosselin completed his Ph.D. in Pharmaceutics and Pharmaceutical Chemistry at The Ohio State University, where he also earned his B.S. in Biology. His academic background laid the foundation for his expertise in pharmaceutical manufacturing and biopharmaceutics. His knowledge extends to various aspects of the pharmaceutical industry, including pharmacokinetics and analytical chemistry.
Professional Expertise
Michael Gosselin has a well-rounded expertise in pharmaceutical manufacturing, particularly in oral solid dose formulations. He is knowledgeable in preparing CMC sections of regulatory filings such as ANDA, NDA, DMF, IND, and CBE. He is proficient in the design of experiments (DOE) and in silico modeling using GastroPlus. His background in biotechnology and gene therapy, coupled with his international experience, enhances his ability to manage diverse teams and projects effectively.